Comparison of the clinical efficacy of celebrex and celecoxib for pain relief after periodontal surgeries

 Currently one of the most common problems in dentistry is effective pain management after dental surgeries. Celecoxib is the only specific COX-2 inhibitor used in Iran.

The aim of this study was to determine the effectiveness of Celecoxib (an Iranian product) and Celebrex in pain relief after periodontal surgery.

This randomized double-blind cross-over clinical trial was conducted on 30 patients with chronic periodontitis. The patients underwent surgical procedures on two posterior symmetric sextant with a 4-week interval. The patients were assigned to 2 groups:Group A: 200mg of Celebrex under the brand name, (bid) and group B:200 mg of Celecoxib (bid). The patients reported their pain level using VAS (visual analog scale) 1, 3, 6, 12, 24 and 48 hours after periodontal surgery. Data were analyzed with SPSS 15, using Mann-Whitney and Freidman’s tests.

Statistical analysis of data showed significant differences between Celecoxib and Celebrex 1, 3, 6, 12 and 24 hours after surgery (P<0.05). In each group there were significant differences between different postoperative intervals (P<0.05).

Considering the lower rate of side effects of COX-2 specific inhibitors, if the patients have no financial problems, Celebrex can be a proper choice for pain management after periodontal surgeries.